VAPrapid-2 is a randomised controlled trial that aims to test whether a rapid, biomaker-based exclusion of ventilator-associated pneumonia (VAP) can improve antibiotic stewardship for this group of patients.

Patients are recuited from 23 Intensive Care Units in the UK.


Chief Investigator: Professor John Simpson

Clinical Research Associate: Dr Tom Hellyer

Trial Manager: Jennie Parker


Funder: The Wellcome Trust and the Department of Health

Industry partner: Becton Dickinson Biosciences


Trial Registration: ISRCTN65937227